Alnylam ALN-APP-001: Phase I, placebo-controlled trial of ALN-APP in participants with Early-Onset Alzheimer’s disease

J
Jared Brosch, MD

Primary Investigator

Recruiting
18 years - 100 years
All
Phase 1
4 participants needed
3 Locations

Brief description of study

Who is Eligible
  • Ages 18+
  • Must have had symptoms of Alzheimer’s disease prior to age 65
  • Diagnosis of Alzheimer’s disease
  • Must be able to complete MRI
  • Must be able to tolerate lumbar puncture
  • No history of seizures, stroke or cancer in the last 5 years

What is Involved
  • In-person visits at IUH Neuroscience Center and University Hospital
  • Participants will receive at least one dose of medication injected by a physician into their spinal canal with local anesthesia.  Participants will stay overnight at University Hospital directly following the first injection of medication.  
  • Participation will last 6 months to 12 months following administration, for blood work and imaging analysis

Compensation
  • Compensation available via payment card for each completed appointment

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alzheimer’s disease
  • Age: 18 years - 100 years
  • Gender: All


Updated on 01 Aug 2024. Study ID: 14597

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team